A phase I/II study of 18F-OP-801 in combination with OP-101 in amyotrophic lateral sclerosis (ALS) patients
Latest Information Update: 25 Oct 2023
At a glance
- Drugs OP-101 (Primary) ; OP-801 (Primary)
- Indications Amyotrophic lateral sclerosis; Multiple sclerosis
- Focus Diagnostic use
- 09 Oct 2023 According to an Ashvattha Therapeutics media release, readout from this study will be presented in the first half of 2024.
- 29 Sep 2021 According to an Ashvattha Therapeutics media release, the company plans to initiate this phase I/II study in early 2022 and expects to report imaging data in second half of 2022.
- 18 Dec 2020 New trial record